Back to today’s briefing

Story perspectives

Ozempic Faces Generic Competition in India, Prices to Drop

3/31/2026

41 7 Full Breakdown

Summary

Story summary

Novo Nordisk's weight loss drug Ozempic will face generic competition in India after its patent expires.
The first generics are expected to enter the Indian market.
Novo Nordisk plans to cut prices in India by 30-50% to defend market share.
Local generics are priced as low as INR1,290 in India.
The generics' entry is expected to lower prices by 40-50% by FY27, challenging Novo Nordisk's premium brand image.

1 of 1

Story summary

Novo Nordisk's weight loss drug Ozempic will face generic competition in India after its patent expires.
The first generics are expected to enter the Indian market.
Novo Nordisk plans to cut prices in India by 30-50% to defend market share.
Local generics are priced as low as INR1,290 in India.
The generics' entry is expected to lower prices by 40-50% by FY27, challenging Novo Nordisk's premium brand image.